Skip to content

Evaluation of a Novel Auto-Adjusting Positive Airway Pressure Algorithm for the Treatment of Obstructive Sleep Apnea Clinical Study

Evaluation of a Novel Auto-Adjusting Positive Airway Pressure Algorithm for the Treatment of Obstructive Sleep Apnea Clinical Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06769607
Enrollment
80
Registered
2025-01-10
Start date
2025-04-10
Completion date
2025-12-31
Last updated
2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea

Brief summary

This study aims to assess the effectiveness of an investigational algorithm in the treatment of obstructive sleep apnea.

Detailed description

This is a blind, randomized cross over (or single arm depending on phase) study aiming to show that the new algorithm is efficacious in the treatment of obstructive sleep apnea (OSA). Furthermore, it allows for the comparison of relevant objective data parameters from the device and subjective outcomes in comparison to an established algorithm. This study is planned in two phases. Phase 1 aims to gain confidence that the algorithm is functioning as intended, and allow for minor modifications to be made to the software before proceeding to Phase 2. Phase 2 aims to assess the performance of the algorithm in a broader range of participants to capture data and subjective feedback comparing the users experience between the new algorithm and the control algorithm. After the conclusion of phase 1 and 2, an optional extended trial period will be offered to participants who indicate that the experience on the investigational device was satisfactory and would like to continue using the algorithm will be included in an optional extended trial period. The study will be conducted in the home environment. Participants who met the inclusion/exclusion criteria will be contacted. Participants will be explained the details of the trial and those who wish to take part will be invited to a selected site for the first study visit. In addition, subjects may be asked if they are willing to wear a wearable during both day and night (unless charging) for the duration of the study iteration. The wearable will be a commercially available wellness wearable that collects data to provide information about sleep and activity. Visit 1 Participants will provide written informed consent. Participants will be set up on the algorithm they are first randomized to. If the participant and assessor are happy to proceed, the participants will take the device home to trial the first randomized algorithm, participants will be asked to complete a questionnaire regarding their therapy experience. Visit 2 Participants will then be switched to the alternative algorithm and take the study device home to test. After trialling the second algorithm, participants will be asked to complete a questionnaire regarding their therapy experience and overall preferences. Note: Visit 2 is not required if a cross over is not required in Phase 1. Visit 3 The participant will return the investigational device to the assessor. The participants' questionnaire responses will be reviewed. Participants will be reimbursed. This concludes the participation in the study.

Interventions

DEVICEInvestigational algorithm

Investigational algorithm developed for the treatment of Obstructive Sleep Apnea.

DEVICEControl algorithm

Released algorithm intended for the treament of Obstructive Sleep Apnea

Sponsors

ResMed
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Single (Participant)

Intervention model description

This is a blind, randomized cross over (or single arm) study aiming to show that the new algorithm is efficacious in the treatment of OSA. Furthermore, it allows for the comparison of relevant objective data parameters from the device, wearable data and subjective outcomes in comparison to an established algorithm. The study is planned in two phases. Phases may be repeated until sufficient confidence is gained of the intended behavior of the investigational algorithm and to ensure that the sample has appropriate coverage of different user experiences which can impact study outcomes (e.g. comfort settings such as soft response). After the conclusion of phase 1 and 2, participants who indicate that the experience on the investigational device was satisfactory and would like to continue using the algorithm will be included in an optional extended trial period.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants willing to give written informed consent. * Participants who can read and comprehend English. * Participants who ≥ 18 years of age * Participants who have been using a ResMed AirSense 10 or 11 device. * Participants currently using AutoSet (APAP) mode. * Participants being established on PAP therapy for the treatment of OSA for approximately \>3 months. * Participants who can participate in the study for up to 8 weeks.

Exclusion criteria

* Participants using Bilevel flow generators. * Participants using CPAP, AutoSet for Her * Participants who are or may be pregnant. * Participants with a preexisting lung disease/ condition that would predispose them to pneumothorax (for example: COPD, lung cancer; fibrosis of the lungs; recent (\< 2years) case of pneumonia or lung infection; lung injury. * Participants believed to be unsuitable for inclusion by the researcher. * Participants who are currently enrolled in other medical clinical studies

Design outcomes

Primary

MeasureTime frameDescription
Comparison of the algorithm efficacy (AHI) to a clinically relevant data8 weeksThe mean residual AHI of the investigational algorithm will be compared against an excepted clinical benchmark of 5 using a one sample t test.

Secondary

MeasureTime frameDescription
Secondary endpoint: LeakFrom enrollment to the end of each study arm (up to 8 weeks)Hypothesis: the investigational algorithm will be equivalent or better than the comparison algorithm. Objective statistics on Leak in litres per minute (L/min) stored in the PAP device will be downloaded. These parameters will be captured from each arm of testing and results will be analysed and compared.
Secondary endpoint: PressureFrom enrolment to the end of each study arm (up to 8 weeks)Hypothesis: the investigational algorithm will be equivalent or better than the comparison algorithm. Objective statistics on Pressure in centimeters of water (cmH2O) stored in the PAP device will be downloaded. These parameters will be captured from each arm of testing and results will be analysed and compared.
Secondary endpoint: Device usageFrom enrolment to the end of each study arm (up to 8 weeks)Hypothesis: the investigational algorithm will be equivalent or better than the comparison algorithm. Objective statistics on Device usage in hours per day (Hrs) stored in the PAP device will be downloaded. These parameters will be captured from each arm of testing and results will be analysed and compared.
Wearable data - Sleep metricsFrom enrolment to the end of each study arm (up to 8 weeks)Hypothesis: the investigational algorithm will be equivalent or better than the comparison algorithm. Objective statistics on sleep metrics measured via the wearable will be downloaded. These parameters will be captured from each arm of testing and results will be analysed and compared.
Wearable data - Activity MetricsFrom enrolment to the end of each study arm (up to 8 weeks)Hypothesis: the investigational algorithm will be equivalent or better than the comparison algorithm. Objective statistics on activity metrics measured via the wearable will be downloaded. These parameters will be captured from each arm of testing and results will be analysed and compared.
Secondary endpoint: Subjective scoresFrom enrolment to the end of each study arm (up to 8 weeks)Hypothesis: the investigational algorithm will be equivalent or better than the comparison algorithm and/or Criterion score of 6. Subjective scores will be collected from participants on each item (e.g. comfort, breathign comfort, ease of falling asleep). Scores will be collected using an 11-point Likert Scale where a score of 10 is considered very favorable whereas score of 0 is considered very unfavorable.

Countries

Australia

Contacts

Primary ContactSumudu Herath
sumudu.herath@resmed.com.au+61 288841722

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026